Anti-Mouse Galectin-9 [RG9-1] In Vivo Antibody - Low Endotoxin
Introducing the Anti-Mouse Galectin-9 [RG9-1] In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo applications. This antibody specifically targets Galectin-9, a key protein involved in immune response regulation, making it an ideal tool for research in immunology, oncology, and related fields. With a rat IgG2a isotype, it ensures high purity and extremely low endotoxin levels (<1.0 EU/mg), making it perfect for applications such as ELISA, flow cytometry, immunohistochemistry, and other assays. Available in various sizes, it is formulated in sterile phosphate-buffered saline for optimal stability and performance.
Galectin-9 is a crucial glycoprotein involved in numerous biological processes, including modulation of immune cell function and apoptosis. It has significant implications in cancer research, autoimmune diseases, and inflammatory responses due to its role in regulating T-cell and macrophage activity, making the Anti-Mouse Galectin-9 [RG9-1] In Vivo Antibody an indispensable asset for advancing your research. Enhance your studies with this reliable and versatile antibody.
Product Name:
Anti-Mouse Galectin-9 (Clone RG9-1) In Vivo Antibody - Low Endotoxin
Product Code:
IVMB0333
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
RG9-1
Protein:
Galectin-9
Product Type:
Monoclonal Antibody
Synonyms:
Galectin-9, RG9-1
Isotype:
IgG2b k
Reactivity:
Mouse
Applications:
B, In Vivo
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% by SDS Page â‹… ≥95% monomer by analytical SEC
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
B, In Vivo
Reactivity:
Mouse
Host Species:
Rat
Specificity:
RG9-1 activity is directed against mouse galectin-9.
Antigen Distribution:
Galectin-9 is expressed by many cell types, including T cells, B cells, macrophages, dendritic cells, astrocytes, mast cells, eosinophils, fibroblasts, endothelial cells, and epithelial cells.
Immunogen:
Recombinant mouse galectin-9
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% by SDS Page â‹… ≥95% monomer by analytical SEC
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Galectin-9 (Gal-9), a member of the galectin family of mammalian lectins, binds β-galactoside. Gal-9 is expressed by many cell types, including endothelial cells, the epithelium of the gastrointestinal tract, T cells, B cells, macrophages, and mast cells1. Gal-9 plays a significant role in innate and adaptive immunity and regulates excessive immunity by suppressing interleukin (IL)-17 producing effector T helper cells (Th)17 and Th1 as well as by augmenting Foxp3+ regulatory T cells (Treg). In addition, Gal-9 induces monocytic myeloid-derived suppressor cells (MDSCs), granulocytic MDSCs, and plasmacytoid dendritic cell-like macrophages. Gal-9 also suppresses B cell receptor signaling and is regulated by I-branching of N-glycans2. Additionally, Gal-9 stimulates the maturation of dendritic cells3.
Gal-9 is thought to function by binding to specific carbohydrate moieties in receptor molecules expressed on the surface of its target cells, including the T-cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3)1. Gal-9 is predominantly located in the cytoplasm but can also be secreted3. Gal-9 is expressed by a variety of tumor cells, plays a role in tumor immunity, and can suppress tumor metastasis by blocking adhesion to endothelium and extracellular matrices4. CD45, which regulates antigen receptor signaling, is a major glycoprotein receptor for Gal-9 on naive B cells2.
Protein:
Galectin-9
Ligand/Receptor:
Binds to β-galactosides and can serve as a ligand for TIM-3 (CD366)
